c-Met/HGFR
Os inibidores de c-Met/HGFR visam o Receptor do Fator de Crescimento de Hepatócitos (c-Met), uma tirosina quinase envolvida em processos celulares como crescimento, motilidade e morfogênese. A sinalização de c-Met está implicada na progressão do câncer, na metástase e na resistência às terapias. Inibir o c-Met pode interromper o crescimento e a disseminação do tumor, tornando esses inibidores valiosos na pesquisa sobre o câncer. Na CymitQuimica, oferecemos inibidores de c-Met/HGFR para apoiar sua pesquisa em oncologia, metástase e terapias contra o câncer.
Foram encontrados 143 produtos de "c-Met/HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
c-Met-IN-16
CAS:c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research .Fórmula:C21H17F2N9OCor e Forma:SolidPeso molecular:449.42Vabametkib
CAS:Vabametkib: potent HGFR inhibitor, IC50 = 7 nM, halts Hs746T cell growth, used in cancer therapy.Fórmula:C29H34N12OCor e Forma:SolidPeso molecular:566.66Boditrectinib
CAS:Boditrectinib: potent TKI, anti-cancer, researches cancer, inflammation, neurodegeneration, infections.Fórmula:C23H24F2N6OCor e Forma:SolidPeso molecular:438.47SAR125844
CAS:SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)Fórmula:C25H23FN8O2S2Pureza:98.73%Cor e Forma:SolidPeso molecular:550.63Ref: TM-T5467
1mg34,00€5mg74,00€10mg110,00€25mg215,00€50mg344,00€100mg557,00€200mg790,00€1mL*10mM (DMSO)92,00€Mifanertinib dimaleate
CAS:Mifanertinib dimaleate is a potent tyrosine kinase inhibitor with antineoplastic activity .Fórmula:C29H27ClF3N5O10Cor e Forma:SolidPeso molecular:698Tyrosine kinase-IN-4
CAS:Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor [1].Fórmula:C23H21N3O3Cor e Forma:SolidPeso molecular:387.43T-1840383
CAS:T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.Fórmula:C30H25ClFN5O4Cor e Forma:SolidPeso molecular:574(R)-Afatinib
CAS:(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.Fórmula:C24H25ClFN5O3Cor e Forma:SolidPeso molecular:485.94c-Met-IN-12
CAS:c-Met-IN-12: potent c-Met/AXL/Mer/TYRO3 inhibitor, IC50=10.6 nM, oral, anti-tumor, scaffold for selectivity enhancement.Fórmula:C34H29FN4O4Cor e Forma:SolidPeso molecular:576.62Dalmelitinib
CAS:Dalmelitinib: oral c-Met kinase inhibitor, IC50 2.9 nM, disrupts MET, AKT, ERK in cancer cells, for NSCLC research.Fórmula:C22H16FN7O2SCor e Forma:SolidPeso molecular:461.47MK-8033 hydrochloride
CAS:MK-8033 hydrochloride is an oral ATP-competitive c-Met/Ron inhibitor (IC50: c-Met 1nM, Ron 7nM), used for various cancers including NSCLC.Fórmula:C25H22ClN5O3SCor e Forma:SolidPeso molecular:507.99c-Met-IN-13
CAS:c-Met-IN-13: potent c-Met inhibitor (IC50 2.43 nM), exhibits anti-proliferative, cytotoxic effects; potential cancer therapy.Fórmula:C30H28F2N2O6Cor e Forma:SolidPeso molecular:550.55Emzeltrectinib
CAS:Emzeltrectinib is a potent tyrosine kinase inhibitor with antineoplastic activity .Fórmula:C17H15F3N6OCor e Forma:SolidPeso molecular:376.34c-met-IN-1
CAS:c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.Fórmula:C35H37FN6O5Pureza:98%Cor e Forma:SolidPeso molecular:640.7MET kinase-IN-3
CAS:MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.Fórmula:C25H16ClF2N5O2Cor e Forma:SolidPeso molecular:491.88(3S,4S)-Tivantinib
CAS:(3S,4S)-Tivantinib, a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET, targets GSK3α and GSK3β—two novel enzymes implicated in theFórmula:C23H19N3O2Cor e Forma:SolidPeso molecular:369.42OSI-296
CAS:OSI-296: potent cMET/RON inhibitor (IC50: 42/200 nM), effective in tumor models, tolerable, oral, reduces bone tumor growth.Fórmula:C21H19Cl2FN4O3Pureza:98%Cor e Forma:SolidPeso molecular:465.3Tyrosine kinase-IN-6
CAS:Tyrosine kinase-IN-6 is a potent inhibitor of RON splice variants, demonstrating significant anticancer and antineoplastic effects [1].Fórmula:C37H31F2N5O5SPureza:98%Cor e Forma:SolidPeso molecular:695.73SOMG-833 HCl
CAS:SOMG-833 HCl is a selective inhibitor of c-MET. It acts by blocking c-MET dependent neoplastic effects and exerting antitumor activity.Fórmula:C22H22F3N5O2Pureza:98%Cor e Forma:SolidPeso molecular:445.44(rel)-Tivantinib
CAS:(rel)-Tivantinib is a potent, highly selective inhibitor of the receptor tyrosine kinase c-MET and has additional novel targets, GSK3α and GSK3β, that areFórmula:C23H19N3O2Cor e Forma:SolidPeso molecular:369.42
